|Bid||23.06 x 800|
|Ask||24.57 x 800|
|Day's Range||21.02 - 23.38|
|52 Week Range||20.49 - 97.43|
|Beta (5Y Monthly)||1.56|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 22, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||86.26|
Fate Therapeutics, Inc. ( NASDAQ:FATE ) shareholders might understandably be very concerned that the share price has...
SAN DIEGO, May 06, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences: BofA Securities 2022 Healthcare Conference on Thursday, May 12, 2022 at 12:20 PM ET in Las Vegas, NevadaH.C. Wainwright Annual Global Life Science
FATE reports a narrower loss and higher collaboration revenues in the first quarter.